Scientific review of phase I protocols with novel dose-escalation designs: How much information is needed?

Journal of Clinical Oncology

Volumn 33, Issue 19, 2015, Pages 2221-2225

  Iasonos, Alexia ^a   Gönen, Mithat ^a   Bosl, George J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOSE CALCULATION; DRUG DESIGN; DRUG DOSE ESCALATION; DRUG RESEARCH; DRUG SAFETY; HUMAN; PATIENT SAFETY; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; STUDY DESIGN; MAXIMUM TOLERATED DOSE; METHODOLOGY; ONCOLOGY; STANDARDS; STATISTICAL ANALYSIS;

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; DATA INTERPRETATION, STATISTICAL; HUMANS; MAXIMUM TOLERATED DOSE; MEDICAL ONCOLOGY; RESEARCH DESIGN;

EID: 84937133576     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.59.8466     Document Type: Review

References (20)

1. O'Quigley J, Pepe M, Fisher L: Continual reassessment method: A practical design for phase 1 clinical trials in cancer. Biometrics 46:33-48, 1990
2. Iasonos A, Wilton AS, Riedel ER, et al: A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies. Clin Trials 5:465-477, 2008
3. Iasonos A, O'Quigley J: Design considerations for dose-expansion cohorts in phase I trials. J Clin Oncol 31:4014-4021, 2013
4. O'Quigley J, Shen LZ: Continual reassessment method: A likelihood approach. Biometrics 52:673-684, 1996
5. Shu J, O'Quigley J: Dose-escalation designs in oncology: ADEPT and the CRM. Stat Med 27: 5345-5353, 2008; discussion 5354-5355
6. O'Quigley J, Paoletti X: Continual reassessment method for ordered groups. Biometrics 59: 430-440, 2003
7. Cheung YK: Simple benchmark for complex dose finding studies. Biometrics 70:389-397, 2014
8. Moroney J, Fu S, Moulder S: Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: Tolerance and biological activity. Clin Cancer Res 18: 5796-5805, 2012
9. Le Tourneau C, Stathis A, Vidal L, et al: Choice of starting dose for molecularly targeted agents evaluated in first-in-human phase I cancer clinical trials. J Clin Oncol 28:1401-1407, 2010
10. Iasonos A, O'Quigley J: Adaptive dose-finding studies: A review of model-guided phase I clinical trials. J Clin Oncol 32:2505-2511, 2014
11. Lee SM, Cheung YK: Calibration of prior variance in the Bayesian continual reassessment method. Stat Med 30:2081-2089, 2011
12. Iasonos A, O'Quigley J: Interplay of priors and skeletons in two-stage continual reassessment method. Stat Med 31:4321-4336, 2012
13. Berger JO: An overview of robust Bayesian analysis (with discussion). TEST 3:5-124, 1994
14. Babb J, Rogatko A, Zacks S: Cancer phase I clinical trials: Efficient dose escalation with overdose control. Stat Med 17:1103-1120, 1999
15. Goodman SN, Zahurak ML, Piantadosi S: Some practical improvements in the continual reassessment method for phase I studies. Stat Med 14:1149-1161, 1995
16. Paoletti X, Le Tourneau C, Verweij J, et al: Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: Results of a DLT-TARGETT international survey. Eur J Cancer 50: 2050-2056, 2014
17. Wages NA, Conaway MR, et al: Continual reassessment method for partial ordering. Biometrics 67:1555-1563, 2011
18. Garrett-Mayer E: The continual reassessment method for dose-finding studies: A tutorial. Clin Trials 3:57-71, 2006
19. Hamberg P, Ratain MJ, Lesaffre E, et al: Dose escalation models for combination phase I trials in oncology. Eur J Cancer 46:2870-2878, 2010
20. Neuenschwander B, Branson M, and Gsponer T: Critical aspects of the Bayesian approach to phase I cancer trials. Stat Med 27:2420-2439, 2008